Navigation Links
Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
Date:5/1/2013

SALT LAKE CITY, May 1, 2013 /PRNewswire-iReach/ -- Tolero Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel therapeutics to treat cancer and other serious human diseases, today announced that it has entered into a license agreement with Sanofi in which it received exclusive worldwide rights to develop and commercialize alvocidib (flavopiridol). Alvocidib is a small molecule inhibitor of the cyclin-dependent kinases that has demonstrated activity in clinical trials in several malignancies, including chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).

Under the terms of the agreement, Tolero Pharmaceuticals will pay Sanofi an undisclosed upfront payment, and future payments on the successful achievement of milestones related to the commercialization of alvocidib. Sanofi will also receive tiered royalties on sales of alvocidib and maintains certain negotiation rights with respect to manufacturing the pharmaceutical product for Tolero and becoming a commercialization partner.

"We are tremendously excited about this new opportunity and feel fortunate to partner with Sanofi on this highly promising asset with near-term commercialization potential," said Dallin Anderson , Chairman and President of Tolero.

Dr. David Bearss , Tolero's Chief Executive Officer, added, "Alvocidib has been evaluated in more than forty Phase I and Phase II clinical trials and has demonstrated remarkable activity in multiple studies of acute and chronic leukemia as both a single agent and in combination with chemotherapy." Tolero continues to advance various preclinical assets targeting areas of unmet need and strong commercial opportunity in the treatment of various cancers.

About Tolero Pharmaceuticals

Tolero is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat and cure cancer and other life-threatening diseases. Tolero has utilized its innovative drug development platform to create a diverse portfolio of candidate agents targeting multiple cancer-associated cellular pathways. Tolero Pharmaceuticals is a privately held company headquartered in Salt Lake City, Utah. For additional information, please visit the company's website at www.toleropharma.com.

Media Contact: Dallin Anderson Tolero Pharmaceuticals, Inc., 801-285-7570, danderson@toleropharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Tolero Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
(Date:10/12/2017)... ... , ... On Saturday, October 21, the Health & Wellness Center at Florida ... money for the American Heart Association Heart Walk. Teams of up to 10 people ... keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on ...
Breaking Medicine News(10 mins):